Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 178

1.

Interplay Between Reversible Phosphorylation and Irreversible Adp-Ribosylation of Eukaryotic Translation Elongation Factor 2.

Mateus-Seidl R, Stahl S, Dengl S, Birzele F, Herrmuth H, Mayer K, Niederfellner G, Liu XF, Pastan I, Brinkmann U.

Biol Chem. 2018 Sep 1. pii: /j/bchm.just-accepted/hsz-2018-0280/hsz-2018-0280.xml. doi: 10.1515/hsz-2018-0280. [Epub ahead of print]

PMID:
30218597
2.

Transcytosis of payloads that are non-covalently complexed to bispecific antibodies across the hCMEC/D3 blood-brain barrier model.

Schmid D, Buntz A, Hanh Phan TN, Mayer K, Hoffmann E, Thorey I, Niewöhner J, Vasters K, Sircar R, Mundigl O, Kontermann RE, Brinkmann U.

Biol Chem. 2018 Jun 27;399(7):711-721. doi: 10.1515/hsz-2017-0311.

PMID:
29466231
3.

Corrigendum to "Bispecific antibodies" [Drug Discov. Today 20 (July (7)) (2015) 838-847].

Kontermann RE, Brinkmann U.

Drug Discov Today. 2018 Jan 5. pii: S1359-6446(17)30598-6. doi: 10.1016/j.drudis.2017.12.004. [Epub ahead of print] No abstract available.

PMID:
29309739
4.

The Role of micro RNAs in Breast Cancer Metastasis: Preclinical Validation and Potential Therapeutic Targets.

Weidle UH, Dickopf S, Hintermair C, Kollmorgen G, Birzele F, Brinkmann U.

Cancer Genomics Proteomics. 2018 Jan-Feb;15(1):17-39. Review.

5.

Disruption of diphthamide synthesis genes and resulting toxin resistance as a robust technology for quantifying and optimizing CRISPR/Cas9-mediated gene editing.

Killian T, Dickopf S, Haas AK, Kirstenpfad C, Mayer K, Brinkmann U.

Sci Rep. 2017 Nov 13;7(1):15480. doi: 10.1038/s41598-017-15206-x.

6.

Influence of DPH1 and DPH5 Protein Variants on the Synthesis of Diphthamide, the Target of ADPRibosylating Toxins.

Mayer K, Schröder A, Schnitger J, Stahl S, Brinkmann U.

Toxins (Basel). 2017 Feb 24;9(3). pii: E78. doi: 10.3390/toxins9030078.

7.

The making of bispecific antibodies.

Brinkmann U, Kontermann RE.

MAbs. 2017 Feb/Mar;9(2):182-212. doi: 10.1080/19420862.2016.1268307. Review.

8.

Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.

Bauss F, Lechmann M, Krippendorff BF, Staack R, Herting F, Festag M, Imhof-Jung S, Hesse F, Pompiati M, Kollmorgen G, da Silva Mateus Seidl R, Bossenmaier B, Lau W, Schantz C, Stracke JO, Brinkmann U, Onda M, Pastan I, Bosslet K, Niederfellner G.

Mol Oncol. 2016 Oct;10(8):1317-29. doi: 10.1016/j.molonc.2016.07.003. Epub 2016 Jul 14.

9.

Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2.

Scheuer W, Thomas M, Hanke P, Sam J, Osl F, Weininger D, Baehner M, Seeber S, Kettenberger H, Schanzer J, Brinkmann U, Weidner KM, Regula J, Klein C.

MAbs. 2016;8(3):562-73. doi: 10.1080/19420862.2016.1147640.

10.

Engineered hapten-binding antibody derivatives for modulation of pharmacokinetic properties of small molecules and targeted payload delivery.

Dengl S, Sustmann C, Brinkmann U.

Immunol Rev. 2016 Mar;270(1):165-77. doi: 10.1111/imr.12386. Review.

11.

Bispecific Antibodies for Targeted Delivery of Dendritic Polyglycerol (dPG) Prodrug Conjugates.

Mehrabadi FS, Adelmann J, Gupta S, Wedepohl S, Calderón M, Brinkmann U, Haag R.

Curr Cancer Drug Targets. 2016;16(7):639-49.

PMID:
26853135
12.

TriFabs--Trivalent IgG-Shaped Bispecific Antibody Derivatives: Design, Generation, Characterization and Application for Targeted Payload Delivery.

Mayer K, Baumann AL, Grote M, Seeber S, Kettenberger H, Breuer S, Killian T, Schäfer W, Brinkmann U.

Int J Mol Sci. 2015 Nov 17;16(11):27497-507. doi: 10.3390/ijms161126037.

13.

Acoustic Coordinated Reset Neuromodulation in a Real Life Patient Population with Chronic Tonal Tinnitus.

Hauptmann C, Ströbel A, Williams M, Patel N, Wurzer H, von Stackelberg T, Brinkmann U, Langguth B, Tass PA.

Biomed Res Int. 2015;2015:569052. doi: 10.1155/2015/569052. Epub 2015 Oct 19.

14.

Hapten-Binding Bispecific Antibodies for the Targeted Delivery of SiRNA and SiRNA-Containing Nanoparticles.

Thorey IS, Grote M, Mayer K, Brinkmann U.

Methods Mol Biol. 2016;1364:219-34. doi: 10.1007/978-1-4939-3112-5_18.

PMID:
26472454
15.

Loss of diphthamide pre-activates NF-κB and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factor.

Stahl S, da Silva Mateus Seidl AR, Ducret A, Kux van Geijtenbeek S, Michel S, Racek T, Birzele F, Haas AK, Rueger R, Gerg M, Niederfellner G, Pastan I, Brinkmann U.

Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10732-7. doi: 10.1073/pnas.1512863112. Epub 2015 Aug 10.

16.

Induction of heat shock protein HSPA6 (HSP70B') upon HSP90 inhibition in cancer cell lines.

Kuballa P, Baumann AL, Mayer K, Bär U, Burtscher H, Brinkmann U.

FEBS Lett. 2015 Jun 4;589(13):1450-8. doi: 10.1016/j.febslet.2015.04.053. Epub 2015 May 7.

17.

Bispecific antibodies.

Kontermann RE, Brinkmann U.

Drug Discov Today. 2015 Jul;20(7):838-47. doi: 10.1016/j.drudis.2015.02.008. Epub 2015 Feb 26. Review. Erratum in: Drug Discov Today. 2018 Jan 5;:.

18.

Hapten-directed spontaneous disulfide shuffling: a universal technology for site-directed covalent coupling of payloads to antibodies.

Dengl S, Hoffmann E, Grote M, Wagner C, Mundigl O, Georges G, Thorey I, Stubenrauch KG, Bujotzek A, Josel HP, Dziadek S, Benz J, Brinkmann U.

FASEB J. 2015 May;29(5):1763-79. doi: 10.1096/fj.14-263665. Epub 2015 Feb 10.

19.

Tumor-antigen-binding bispecific antibodies for cancer treatment.

Weidle UH, Kontermann RE, Brinkmann U.

Semin Oncol. 2014 Oct;41(5):653-60. doi: 10.1053/j.seminoncol.2014.08.004. Epub 2014 Aug 12. Review.

20.

Zirconium-89 labeled antibodies: a new tool for molecular imaging in cancer patients.

van de Watering FC, Rijpkema M, Perk L, Brinkmann U, Oyen WJ, Boerman OC.

Biomed Res Int. 2014;2014:203601. doi: 10.1155/2014/203601. Epub 2014 May 28. Review.

21.

A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.

Schanzer JM, Wartha K, Croasdale R, Moser S, Künkele KP, Ries C, Scheuer W, Duerr H, Pompiati S, Pollman J, Stracke J, Lau W, Ries S, Brinkmann U, Klein C, Umana P.

J Biol Chem. 2014 Jul 4;289(27):18693-706. doi: 10.1074/jbc.M113.528109. Epub 2014 May 19.

22.

Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer.

Weidle UH, Tiefenthaler G, Schiller C, Weiss EH, Georges G, Brinkmann U.

Cancer Genomics Proteomics. 2014 Jan-Feb;11(1):25-38. Review.

PMID:
24633317
23.

The translational potential for target validation and therapy using intracellular antibodies in oncology.

Weidle UH, Maisel D, Brinkmann U, Tiefenthaler G.

Cancer Genomics Proteomics. 2013 Nov-Dec;10(6):239-50. Review.

PMID:
24336633
24.

Quantification of cell surface proteins with bispecific antibodies.

Panke C, Weininger D, Haas A, Schelter F, Schlothauer T, Bader S, Sircar R, Josel HP, Baer U, Burtscher H, Mundigl O, Grote M, Brinkmann U, Sustmann C.

Protein Eng Des Sel. 2013 Oct;26(10):645-54. doi: 10.1093/protein/gzt035. Epub 2013 Aug 19.

25.

The emerging role of new protein scaffold-based agents for treatment of cancer.

Weidle UH, Auer J, Brinkmann U, Georges G, Tiefenthaler G.

Cancer Genomics Proteomics. 2013 Jul-Aug;10(4):155-68. Review.

PMID:
23893924
26.

PK modulation of haptenylated peptides via non-covalent antibody complexation.

Hoffmann E, Konkar A, Dziadek S, Josel HP, Conde-Knape K, Kropp H, Kling L, Stubenrauch K, Thorey I, Dengl S, Brinkmann U.

J Control Release. 2013 Oct 10;171(1):48-56. doi: 10.1016/j.jconrel.2013.06.021. Epub 2013 Jun 22.

27.

A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors.

Thomas M, Kienast Y, Scheuer W, Bähner M, Kaluza K, Gassner C, Herting F, Brinkmann U, Seeber S, Kavlie A, Welschof M, Ries S, Weidner KM, Regula JT, Klein C.

PLoS One. 2013;8(2):e54923. doi: 10.1371/journal.pone.0054923. Epub 2013 Feb 6.

28.

The intriguing options of multispecific antibody formats for treatment of cancer.

Weidle UH, Tiefenthaler G, Weiss EH, Georges G, Brinkmann U.

Cancer Genomics Proteomics. 2013 Jan-Feb;10(1):1-18. Review.

PMID:
23382582
29.

Targeted siRNA Delivery and mRNA Knockdown Mediated by Bispecific Digoxigenin-binding Antibodies.

Schneider B, Grote M, John M, Haas A, Bramlage B, Ickenstein LM, Jahn-Hofmann K, Bauss F, Cheng W, Croasdale R, Daub K, Dill S, Hoffmann E, Lau W, Burtscher H, Ludtke JL, Metz S, Mundigl O, Neal ZC, Scheuer W, Stracke J, Herweijer H, Brinkmann U.

Mol Ther Nucleic Acids. 2012 Sep 18;1:e46. doi: 10.1038/mtna.2012.39.

30.

Genetically engineered fusion proteins for treatment of cancer.

Weidle UH, Schneider B, Georges G, Brinkmann U.

Cancer Genomics Proteomics. 2012 Nov;9(6):357-72. Review.

PMID:
23162075
31.

Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing.

Metz S, Panke C, Haas AK, Schanzer J, Lau W, Croasdale R, Hoffmann E, Schneider B, Auer J, Gassner C, Bossenmaier B, Umana P, Sustmann C, Brinkmann U.

Protein Eng Des Sel. 2012 Oct;25(10):571-80. Epub 2012 Sep 13.

32.

Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.

Klein C, Sustmann C, Thomas M, Stubenrauch K, Croasdale R, Schanzer J, Brinkmann U, Kettenberger H, Regula JT, Schaefer W.

MAbs. 2012 Nov-Dec;4(6):653-63. doi: 10.4161/mabs.21379. Epub 2012 Aug 27. Review.

33.

Generation of fluorescent IgG fusion proteins in mammalian cells.

Haas AK, Mayer K, Brinkmann U.

Methods Mol Biol. 2012;901:265-76. doi: 10.1007/978-1-61779-931-0_17.

PMID:
22723107
34.

Bispecific antibody derivatives based on full-length IgG formats.

Grote M, Haas AK, Klein C, Schaefer W, Brinkmann U.

Methods Mol Biol. 2012;901:247-63. doi: 10.1007/978-1-61779-931-0_16.

PMID:
22723106
35.

Fully human targeted cytotoxic fusion proteins: new anticancer agents on the horizon.

Weidle UH, Georges G, Brinkmann U.

Cancer Genomics Proteomics. 2012 May-Jun;9(3):119-33. Review.

PMID:
22593247
36.

Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.

Croasdale R, Wartha K, Schanzer JM, Kuenkele KP, Ries C, Mayer K, Gassner C, Wagner M, Dimoudis N, Herter S, Jaeger C, Ferrara C, Hoffmann E, Kling L, Lau W, Staack RF, Heinrich J, Scheuer W, Stracke J, Gerdes C, Brinkmann U, Umana P, Klein C.

Arch Biochem Biophys. 2012 Oct 15;526(2):206-18. doi: 10.1016/j.abb.2012.03.016. Epub 2012 Mar 21.

PMID:
22464987
37.

Human-protein-derived peptides for intracellular delivery of biomolecules.

Haas AK, Maisel D, Adelmann J, von Schwerin C, Kahnt I, Brinkmann U.

Biochem J. 2012 Mar 15;442(3):583-93. doi: 10.1042/BJ20111973.

PMID:
22150630
38.

Bispecific digoxigenin-binding antibodies for targeted payload delivery.

Metz S, Haas AK, Daub K, Croasdale R, Stracke J, Lau W, Georges G, Josel HP, Dziadek S, Hopfner KP, Lammens A, Scheuer W, Hoffmann E, Mundigl O, Brinkmann U.

Proc Natl Acad Sci U S A. 2011 May 17;108(20):8194-9. doi: 10.1073/pnas.1018565108. Epub 2011 May 2.

39.

Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains.

Schanzer J, Jekle A, Nezu J, Lochner A, Croasdale R, Dioszegi M, Zhang J, Hoffmann E, Dormeyer W, Stracke J, Schäfer W, Ji C, Heilek G, Cammack N, Brandt M, Umana P, Brinkmann U.

Antimicrob Agents Chemother. 2011 May;55(5):2369-78. doi: 10.1128/AAC.00215-10. Epub 2011 Feb 7.

40.

Fluorescent Citrine-IgG fusion proteins produced in mammalian cells.

Haas AK, von Schwerin C, Matscheko D, Brinkmann U.

MAbs. 2010 Nov-Dec;2(6):648-61. doi: 10.4161/mabs.2.6.13179. Epub 2010 Nov 1.

41.

LIGHT (TNFSF14) inhibits adipose differentiation without affecting adipocyte metabolism.

Tiller G, Laumen H, Fischer-Posovszky P, Finck A, Skurk T, Keuper M, Brinkmann U, Wabitsch M, Link D, Hauner H.

Int J Obes (Lond). 2011 Feb;35(2):208-16. doi: 10.1038/ijo.2010.126. Epub 2010 Jun 15.

PMID:
20548299
42.

Polymorphisms of the apoptosis-associated gene DP1L1 (deleted in polyposis 1-like 1) in colon cancer and inflammatory bowel disease.

Wellmann A, Fogt F, Hollerbach S, Hahne J, Koenig-Hoffmann K, Smeets D, Brinkmann U.

J Cancer Res Clin Oncol. 2010 Jun;136(6):795-802. doi: 10.1007/s00432-009-0719-9. Epub 2009 Nov 19.

PMID:
19924442
43.

Effects of TWEAK (TNF superfamily member 12) on differentiation, metabolism, and secretory function of human primary preadipocytes and adipocytes.

Tiller G, Fischer-Posovszky P, Laumen H, Finck A, Skurk T, Keuper M, Brinkmann U, Wabitsch M, Link D, Hauner H.

Endocrinology. 2009 Dec;150(12):5373-83. doi: 10.1210/en.2009-0488. Epub 2009 Nov 3.

PMID:
19887572
44.

Influence of TBK-1 on tumor angiogenesis and microvascular inflammation.

Czabanka M, Korherr C, Brinkmann U, Vajkoczy P.

Front Biosci. 2008 May 1;13:7243-9.

PMID:
18508731
45.

Pseudomonas exotoxin antisense RNA selectively kills hepatitis B virus infected cells.

Hafkemeyer P, Brinkmann U, Brinkmann E, Pastan I, Blum HE, Baumert TF.

World J Gastroenterol. 2008 May 14;14(18):2810-7.

46.

Risk of coronary artery disease as influenced by variants of the human endothelin and endothelin-converting enzyme genes.

Bühler K, Ufer M, Müller-Marbach A, Brinkmann U, Laule M, Stangl V, Roots I, Stangl K, Cascorbi I.

Pharmacogenet Genomics. 2007 Jan;17(1):77-83.

PMID:
17264805
47.

Identification of proangiogenic genes and pathways by high-throughput functional genomics: TBK1 and the IRF3 pathway.

Korherr C, Gille H, Schäfer R, Koenig-Hoffmann K, Dixelius J, Egland KA, Pastan I, Brinkmann U.

Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4240-5. Epub 2006 Mar 6.

48.

Cholesterol reduces membrane electroporation and electric deformation of small bilayer vesicles.

Kakorin S, Brinkmann U, Neumann E.

Biophys Chem. 2005 Sep 1;117(2):155-71.

PMID:
15923075
49.

Common denominator procedure: a novel approach to gene-expression data mining for identification of phenotype-specific genes.

Korn R, Röhrig S, Schulze-Kremer S, Brinkmann U.

Bioinformatics. 2005 Jun 1;21(11):2766-72. Epub 2005 Apr 6.

PMID:
15814560
50.

High throughput functional genomics: identification of novel genes with tumor suppressor phenotypes.

Koenig-Hoffmann K, Bonin-Debs AL, Boche I, Gawin B, Gnirke A, Hergersberg C, Madeo F, Kazinski M, Klein M, Korherr C, Link D, Röhrig S, Schäfer R, Brinkmann U.

Int J Cancer. 2005 Jan 20;113(3):434-9.

Supplemental Content

Loading ...
Support Center